← All trials
NCT06998108
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 9, 2022
- Primary completion
- Dec 31, 2025
- Completion date
- Jun 30, 2026
- First posted
- May 31, 2025
- Last posted
- May 31, 2025
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou BeBetter Medicine Technology Co, LTDLead sponsor
- Chinese Academy of Medical SciencesCollaborator
- Chinese Academy of Medical SciencesOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.